Oscillometric devices are being widely used for ambulatory, home and office blood pressure (BP) measurement, and several of them have been validated using established protocols. This cross-sectional study assessed the impact on antihypertensive treatment decisions of replacing the mercury sphygmomanometer by a validated oscillometric device. Consecutive subjects attending a hypertension clinic had triplicate simultaneous same-arm BP measurements using a mercury sphygmomanometer and a validated professional oscillometric device. For each device, uncontrolled hypertension was defined as average BP X140/90 mm Hg (systolic/diastolic). A total of 5108 simultaneous BP measurements were obtained from 763 subjects in 1717 clinic visits. In 24% of all visits, the mercury and the oscillometric BP measurements led to different conclusion regarding the diagnosis of uncontrolled hypertension. In 4.9% of the visits, the diagnostic disagreement was considered as 'clinically important' (BP exceeding the diagnostic threshold by 45 mm Hg). These data suggest that the replacement of the mercury sphygmomanometer by a validated professional oscillometric device will result into different treatment decisions in about 5% of the cases. Therefore, and because of the known problems when using mercury devices and the auscultatory technique in clinical practise, the oscillometric devices are regarded as reliable alternatives to the mercury sphygmomanometer for office use.
Introduction
Virtually all the evidence on the risks associated with elevated blood pressure (BP) and the benefits of treatment induced BP decline has been obtained using measurements of BP taken by observers using mercury sphygmomanometers and the auscultatory technique.
1,2 Therefore, BP measurement using a mercury sphygmomanometer is regarded as the cornerstone of hypertension diagnosis and management. 1, 2 There are two major issues regarding the auscultatory BP measurement using a mercury sphygmomanometer. One is related to the auscultatory method and the other to the mercury device. Regarding the auscultatory method, despite its wide use by physicians for decades, it is recognized that usually this not properly applied and might therefore not give accurate BP measurements because of the observer prejudice and bias, fast deflation and terminal digit preference. 1, 2 Regarding the use of mercury device, it is recognized that mercury is highly toxic for humans, ecosystems and wildlife, and a European community strategy has been adopted aiming to ban the use of mercury for medical or other purposes. 3 Mercury-free solutions for BP measurement include (a) other devices that use the auscultatory technique (aneroid manometer with an analogue display or electrical pressure transducer with liquid crystal display or light emitting diodes scale, or digital display [4] [5] [6] [7] [8] [9] ) and (b) semi-automated oscillometric devices that measure mean BP and then use a device-specific algorithm to estimate systolic and diastolic BP. 1 Several mercury-free auscultatory and oscillometric devices have been subjected to independent validation using established protocols and proved to be accurate. 10 Therefore, these devices are now recommended for clinical use. 1, 10 The devices that measure BP using the auscultation still have the drawbacks of this method and the need of an observer, whereas the oscillometric devices are fully automated and therefore the observer error and bias is avoided. 1, 2 Oscillometric devices are now almost exclusively used for 24-h ambulatory BP monitoring and are recommended for self-home BP monitoring. 1, 2, 11 However, it is still debated whether the oscillometric devices should replace the mercury sphygmomanometer for the measurement of BP by the doctor in the office or clinic. [12] [13] [14] [15] [16] [17] In 2009, the Scientific Committee on Emerging and Newly Identified Health Risks of the European Commission expressed the opinion that there are no known adverse effects for patients' health because of the replacement of mercury-containing sphygmomanometers by mercury-free alternatives. 18 Indeed, there is no evidence that the replacement of mercury sphygmomanometers by validated mercury-free alternatives might negatively affect patients care. However, a long-term study with randomized controlled design aiming to compare mercury versus mercury-free devices in terms of their long-term effects on morbidity and mortality of hypertensive patients would be a complex undertaking.
This cross-sectional study assessed the impact on antihypertensive treatment decisions of replacing the mercury sphygmomanometer by a validated professional oscillometric device in a hypertension clinic.
Subjects and methods
Consecutive subjects referred to an outpatient hypertension clinic for elevated BP (self-referred or by their family physician), treated or untreated, were recruited. Participants had simultaneous same arm BP measurements (Y connector) using a standard mercury sphygmomanometer (Baumanometer; WA Baum Co. Inc., New York, NY, USA) and a validated professional oscillometric device (BpTRU Medical Devices, Ltd., Coquitlam, BC, Canada; deflation rate 3.5-4.0 mm sec À1 ). 19, 20 This is a standard procedure for routine office BP measurement in the outpatients hypertension clinic since 2003. Three cuffs of different size were used to fit the arm of each individual (inflatable bladder to cover 80-100% of the individual's arm circumference). Clinic BP measurements were performed by three trained observers experienced in BP monitoring research. Before the study initiation and twice during the study period, the observers were retested for their agreement in BP measurement according to the British Hypertension Society protocol 21 and the components of the mercury sphygmomanometers were carefully checked. Triplicate BP measurements were taken per participant at each visit after at least 5 min sitting rest and with at least 30 s between measurements. Subjects with arrhythmia detected by the investigators during the auscultatory BP measurement were excluded. The protocol was approved by the hospital scientific committee, which did not require an informed consent for the analysis of the outpatients' BP data and the retrospective collection of demographic and other data from patients' records.
The data analysis is based on the assessment of average BP of individual 'visits' (three measurements), rather than individual 'BP readings', with some subjects having more than one visit in the study database. The same analysis was repeated by including only the first visit of each subject within the study database (each subject contributing in the analysis with one visit only). The three BP readings taken per clinic visit using the mercury sphygmomanometer and the oscillometric device were averaged to give a single value for systolic and diastolic BP for each measurement method. When fewer than three simultaneous BP measurements were obtained, these data were still included in the analysis, whereas visits with no successful oscillometric measurements were excluded because comparison with auscultatory measurements was not possible. Clinic visits with diagnostic disagreement between the two methods were defined as those with average mercury device systolic BP X140 mm Hg and average oscillometric systolic BP o140 mm Hg, or the reverse. For diastolic BP, diagnostic disagreement was defined as average mercury device measurement X90 mm Hg and oscillometric o90 mm Hg, or the reverse. Diagnostic disagreement was assessed separately for systolic and diastolic BP, and also for systolic and/or diastolic BP. In cases (visits) with diagnostic disagreement between the two methods, the BP difference above the diagnostic threshold of the measurement method that indicated uncontrolled hypertension was classified as: (a) 'arithmetic' disagreement, if the BP difference above the threshold was within 5 mm Hg (140-145 mm Hg for systolic BP and 90-95 mm Hg for diastolic), (b) 'clinically important' disagreement, if the BP difference was 6-10 mm Hg above the threshold (146-150 mm Hg for systolic and 96-100 mm Hg for diastolic), and (c) 'large' disagreement, if it was 410 mm Hg (4150 mm Hg for systolic and 4100 mm Hg for diastolic). Paired t-tests were used to compare measurements taken in the same subjects and w 2 -test to compare categorical variables. Analysis was performed using the Minitab Inc. Statistical Software (release 13.31; Stage College, PA, USA).
Results
A total of 5154 BP readings were collected from 763 subjects in 1718 clinic visits over 14 months (from September 2003 to November 2004). In 31 visits, two valid oscillometric measurements were obtained and in 6 visits only one. In one visit all the three oscillometric BP measurements were erroneous and therefore, this visit was excluded. The analysis is based on 5108 valid simultaneous auscultatory and oscillometric BP readings taken from 763 subjects in 1717 clinic visits. Mean age of the study participants was 58.1 ± 12.9 years, body mass index 27.9±4.3 kg m À2 , 371 women (49%). In this dataset, 40% of subjects had one clinic visit, 26% had two and 34% three or more visits. Average mercury device BP of all 1717 visits was 142 ± 19/ 87±12 mm Hg (systolic/diastolic) and oscillometric 137 ± 19/84 ± 11 (mean difference systolic 4.9 ± 4.8 mm Hg, Po0.0001 and diastolic 3.4 ± 4.3 mm Hg, Po0.0001). Average mercury device BP of the first visit of each participant (n ¼ 763) was 146 ± 20/ 89 ± 12 mm Hg and oscillometric device BP 141 ± 21/ 85±12 mm Hg (mean difference systolic 4.6±5.2 mm Hg, Po0.0001 and diastolic 3.3±4.3 mm Hg, Po0.0001). Data on the prevalence, persistence and predictors of unreliable oscillometric BP measurements from this dataset have been previously reported. 22 In brief, unreliable oscillometric BP measurements were found to be particularly common, not very reproducible and mainly affected by pulse pressure and arm circumference, whereas other factors such as age, gender, body mass index, BP and pulse rate level did not seem to have an independent role. 22 The distribution of average auscultatory BP (763 first visits) was for systolic o120 mm Hg, 121-140, 141-160, 161-180 and 4180 mm Hg 7, 35, 36, 14 and 7%, respectively, and for diastolic o80 mm Hg, 81-90, 91-100, 101-120 and 4120 mm Hg 24, 33, 27, 16 and 1%, respectively,. Analysis of hypertension diagnosis was performed on the basis of all visits (n ¼ 1717) and also on the basis of the first visit of each subject (n ¼ 763).
When BP was assessed using the mercury sphygmomanometer average systolic BP was o140, 140-145 and 4145 mm Hg in 836, 240 and 641 visits, respectively, whereas using the oscillometric device in 1039, 187 and 491 visits, respectively (Po0.001 for difference in BP classification between the two methods). Moreover, using the mercury sphygmomanometer average diastolic BP was o90, 90-95 and 495 mm Hg in 1011, 319 and 387 visits, respectively, whereas using the oscillometric device in 1222, 259 and 236 visits respectively (Po0.001 for difference in BP classification between the two methods). Similar results were found when the same analysis was performed for first visits only (Po0.001).
Out of the 1717 visits, there were 218 (12.7%) with the mercury and the oscillometric systolic BP readings leading to different conclusion regarding the diagnosis of uncontrolled hypertension and 239 (13.9%) for diastolic BP (for first visit analysis 82 (10.7%) and 99 (13.0%) of 763 visits, for systolic and diastolic BP, respectively). The mercury and the oscillometric device BP values in visits with diagnostic disagreement in systolic and diastolic BP are presented in Figure 1 (for all visits and for first visits per participant). In the vast majority of these cases, the mercury device BP measurements indicated uncontrolled hypertension, whereas the corresponding oscillometric measurements were below the diagnostic threshold. When systolic and/or diastolic BP measurements were taken into account, diagnostic disagreement between the mercury and the oscillometric measurements was found in 24.3% of all clinic visits (418 of 1717 visits; 179 with disagreement in systolic BP only, 200 in diastolic BP only, and 39 in both) and 22.3% of the first visits (170 of 763 visits; 71 with disagreement in systolic BP only, 88 in diastolic BP only, and 11 in both). Of the 418 visits with diagnostic disagreement (in systolic and/or diastolic BP), the BP value indicating hypertension was within 5 mm Hg above the diagnostic threshold in 334 (80%; for first visits' analysis in 131 of 170 (77%)).
In 68 (4%) of the total of 1717 visits, the diagnostic disagreement was considered as clinically important with BP (systolic and/or diastolic) exceeding the diagnostic threshold by 6-10 mm Hg (Figure 2 ; for first visit analysis in 33 of 763 visits (4.3%)). The disagreement between the two methods was considered as 'large' with BP exceeding the diagnostic threshold by 410 mm Hg in 16 (0.9%) of the total of 1717 visits and in 6 of 763 first visits (0.8%; Figure 2 ).
Discussion
This study addressed an important clinical issue, which is what would happen regarding the antihypertensive treatment decisions in a hypertension clinic if the conventional mercury sphygmomanometer is replaced by an oscillometric device. The study showed that although arithmetically (BP X1 mm Hg above the threshold) the diagnostic disagreement between the two methods is not uncommon (420% of visits; Figure 2 ), in most of the cases this disagreement is clinically uncertain (BP difference within 5 mm Hg above the diagnostic threshold). Clinically important disagreement (BP 45 mm Hg above the diagnostic threshold) is observed in about 5% of the clinic visits, and large disagreement (BP 410 mm Hg above the threshold) is rare (o1%; Figure 2 ). Because the simultaneous oscillometric and auscultatory BP measurements obtained in this study are equally affected by the random BP variation and the effect of the clinic setting (white coat effect), and the potential observer errors have been corrected by applying a 5 mm Hg grey zone of diagnostic uncertainty, the estimated clinically important diagnostic disagreement between the two measurement methods should be attributed to inherent limitation of the oscillometric BP measurement.
The oscillometric technique is already regarded as the standard method for 24-ambulatory and selfhome BP monitoring, yet its use for office or clinic BP measurement is still debated.
1,2,11-17 Interestingly, several recent long-term outcome hypertension trials involving thousands of patients followed for several years have based recruitment and treatment initiation and titration exclusively on clinic BP measurements taken using oscillometric devices. [23] [24] [25] [26] This was a compromise between the difficulty in standardising auscultatory BP measurements among the hundreds of participating investigators around the world and the imperfect automated oscillometric BP measurement. In addition, in these studies careful attention was not always given to quality BP measurement. For example in the Hypertension Optimal Treatment outcome study 23 that included 18 790 hypertensive subjects randomized to different BP targets, an oscillometric device was used for BP measurement (Visomat OZ, D2, International, Hestia, Germany), the accuracy of which was tested in a questionable study 27 published after the publication of the main results of the Hypertension Optimal Treatment study. Moreover, to date the impact of replacing the mercury sphygmomanometer by oscillometric devices on antihypertensive treatment decisions has not been investigated.
The issue of the accuracy of oscillometric BP monitors has been extensively studied. Several oscillometric monitors have been validated using established protocols and are recommended for ambulatory, home, or office/clinic BP measurement. 10 The oscillometric BP monitor used in this study has been designed for professional use and shown to fulfil the requirements of the American Association for the Advancement of Medical Instrumentation and the British Hypertension Society validation protocol. 19, 20 A combined analysis of two validation studies showed a mean BP difference (versus mercury sphygmomanometer) 0.5 ± 5.4 (s.d.) mm Hg systolic and À2.1±5.9 mm Hg diastolic, with 89 and 96% of the systolic BP differences p5 and 10 mm Hg, respectively, and of the diastolic BP differences 81 and 92%, respectively. 20 Although these data are not directly comparable with this study findings, in the latter the performance of the oscillometric device was as predicted by the validation studies, given that in 87.4% of the 1717 clinic visits (89.3% of first visits) there was agreement in the diagnosis of hypertension made by the auscultatory and the oscillometric systolic BP measurements (for diastolic BP measurements in 86.1 and 87% for all and first visits, respectively; Figure 2 ). In addition, as in the validation studies 20 the average oscillometric-auscultatory BP discrepancy in this study was o5 mm Hg with s.d. o8 mm Hg, which is a validation criterion of the Advancement of Medical Instrumentation protocol. These data suggest that in the clinical setting the tested professional oscillometric device seemed to fulfil the requirements of established validation protocols. The formal validation studies have two deficiencies. First, they assess the BP measurement accuracy in strictly standardised research conditions, whereas this pragmatic study investigated the clinical implications of using a validated oscillometric device in a BP clinic. Second, they allow a considerable level of inaccuracy. For a device that passes the European Society of Hypertension International Protocol, it is accepted to have up to 24% of the BP measurements differing by 410 mm Hg from the reference mercury sphygmomanometer and up to 33% of the subjects having a 45 mm Hg BP difference in two of their three comparisons (in triplicate BP readings). 28 On clinical grounds this allowance might be regarded as unacceptable and it might be argued that the use of oscillometric devices in the office or clinic might alter treatment decision in a large proportion of cases.
An example supporting the view that performing validation studies is not enough and that field tests of new BP measurement technologies in routine conditions of clinical practise are also needed is a recent study that assessed the impact of replacing the conventional mercury sphygmomanometer with a professional oscillometric device (Omron HEM-907XL, Omron Healthcare Europe, Hoofddorp, The Netherlands) in classifying hypertension in a national level health survey in the US population (National Health and Nutrition Examination Survey). 29 Although in that study the oscillometric device seemed to fulfil the Advancement of Medical Instrumentation criteria (mean BP difference and its s.d.), it underestimated the prevalence of hypertension by 2.6%. 29 This finding justifies the 2009 statement by the European Commission Scientific Committee on Emerging and Newly Identified Health Risks Committee, that for ongoing, long-term epidemiological studies currently using mercury sphygmomanometers, it is advisable not to change the method of measurement but to keep mercury sphygmomanometers available in order to compare them with the alternatives. 18 In other words, the Scientific Committee on Emerging and Newly Identified Health Risks Committee took the position that, after formal validation of new technologies, the implications of using them in clinical practise should be also investigated before wide application. 18 This is a field test rather than a research laboratory trial and has neither the elegance nor the complexity of a formal validation study of a BP monitor. The strengths of this analysis are that: (a) this is based on a large sample of visits, (b) BP measurements were obtained in real-life conditions of an outpatient clinic instead of a research setting and (c) simultaneous instead of sequential mercury device and oscillometric measurements have been obtained preventing thereby the influence of BP fluctuations on the comparison of the two methods. This simplified protocol and a single instead of two observers were necessary to shorten the validation procedure in order to be applicable in a large number of subjects in the routine conditions of an outpatients BP clinic. To optimise the quality of clinic BP measurements, three trained observers experienced in BP monitoring research were involved. Before the study initiation and twice during the study period, the observers were retested for agreement in BP measurement according to the British Hypertension Society protocol, 21 and the components of the mercury sphygmomanometers were carefully rechecked. Despite these precautions, the accuracy of the device in this study is expected to be inferior to that achieved in the strictly standardized conditions of a BP monitoring research setting.
The proportion of subjects in this study with diagnostic disagreement between the two methods is striking (Figure 2 ). However, caution is needed in the clinical interpretation of this finding and there are two reasons that a 'clinical correction' should be applied. First, there is an unavoidable source of error with simultaneous auscultatory BP measurement, because the deflation rate of the electronic device was slightly faster (3.5-4.0 mm sec À1 ) compared with that recommended for auscultatory BP measurement (2-3 mm sec À1 ), 1,2 which is expected to lead in underestimation of auscultatory systolic and overestimation of diastolic BP. Second, a small BP difference within 5 mm Hg above the diagnostic threshold (140-145 mm Hg for systolic and 90-95 mm Hg for diastolic BP) should probably be regarded by the clinician as diagnostic uncertainty. For these two reasons it was deemed necessary to correct the 'arithmetic' disagreement between the two methods (within 5 mm Hg away from the diagnostic threshold) by applying a 'grey zone of diagnostic uncertainty' and thereby focusing on 'clinically important' BP differences (45 mm Hg away from the threshold). Such a difference of measured BP away from the threshold (45 mm Hg) cannot be attributed to the effect of the slightly faster deflation rate on auscultatory BP measurement and should not be ignored by the physician as being negligible or uncertain. After applying this correction, clinically important diagnostic disagreement (45 mm Hg in systolic and/or diastolic BP) between the two methods was found in 4.9% of the total study visits and 5.1% of the first visits (Figure 2) . Although in clinical practise treatment decisions should not be made solely on the results of a single measurement or visit, for the purpose of this analysis measurements of a single visit were used to define uncontrolled hypertension.
A 5% prevalence of clinically important disagreement between the two devices is not negligible and should not be ignored. However, it should be taken into account that this study, although not conducted in a research setting as the typical validation studies, was performed in a special hypertension clinic by carefully trained physicians experienced in BP monitoring research. Thus, optimal application of the auscultatory method and maintenance of the mercury devices were ensured, which is not usually the case when these devices are being used by physicians in clinical practise. On the other hand, the oscillometric BP measurements are devoid of the observer bias and error, and the devices require less maintenance than the mercury sphygmomanometer. In other words, in clinical practise it is more feasible to obtain BP measurements as reliable as in the present study using an oscillometric device, rather a mercury sphygmomanometer and auscultation.
In conclusion, these data suggest that the replacement of the conventional mercury sphygmomanometer by a validated professional oscillometric device will result into different treatment decisions in about one out of 20 cases. Therefore, and because of the known problems when using mercury devices and the auscultatory method in clinical practise, the oscillometric devices are regarded as reliable alternatives to the mercury sphygmomanometer for office BP measurement.
